Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Pembrolizumab (MK-3475) as First Line Single Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

Next Previous
X
Search
Trial Profile

Phase II Study of Pembrolizumab (MK-3475) as First Line Single Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Skin cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms CARSKIN

    • Most Recent Events

    • 24 Oct 2023 Results reporting BOR and survival endpoint with a median follow-up of 26 months presented at the 48th European Society for Medical Oncology Congress
    • 06 Jun 2023 Results assessing best ORR and survival endpoints of the entire cohort by PD-L1 status, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Jan 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top